Following in the footsteps of SABCS 2022: top 16 early breast cancer studies that could change our clinical practice: A review

Cover Page

Cite item

Full Text

Abstract

A review of the studies presented at the SABCS 2022 conference on the treatment of breast cancer (BC) has been carried out; 16 of the most exciting and significant works reported at oral or poster sessions have been identified. Data from large randomized and population-based studies were presented, including TAM-01 (the role of adjuvant therapy with 5 mg tamoxifen for in situ cancer), six studies on the surgical treatment of early breast cancer, including a meta-analysis to assess the effect of surgery extent on overall survival, a comparison of the results of targeted lymph node dissection and biopsy of sentinel lymph nodes in patients after neoadjuvant systemic therapy, an analysis of the local relapse rate after breast-conserving surgery in patients with multicentric breast cancer, as well as the effect of carrier status of pathogenic variants of mutations in the ATM, BRCA1, BRCA2, CHEK2 and PALB2 genes on the occurrence of cancer of the contralateral breast. Among the systemic therapy studies, the 10-years results of APT trial, Peony trial were presented, as well as the results of the TMC analysis on the various roles of carboplatin addition in neoadjuvant chemotherapy regimens in patients younger and older than 50 years with triple-negative breast cancer, randomized clinical studies on the escalation of adjuvant endocrine therapy in high relapse risk groups (MonarchE and SWOG S1207), as well as new data on cognitive dysfunction after chemotherapy in patients in the RxPONDER trial. Also noteworthy are the reviews of treatment in special clinical situations: the first results of the POSITIVE trial (an assessment of the oncological and obstetric outcomes of interruption of adjuvant endocrine therapy for conception), an analysis of the mortality of males with breast cancer over the past 20 years, as well as an analysis of the methylmalonic acid effect on senile weakness in patients with early breast cancer.

About the authors

Irina V. Kolyadina

Russian Medical Academy of Continuous Professional Education; Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Author for correspondence.
Email: irinakolyadina@yandex.ru
ORCID iD: 0000-0002-1124-6802

D. Sci. (Med.), Russian Medical Academy of Continuous Professional Education, Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Russian Federation, Moscow; Moscow

References

  1. De Censi A. 10 year results of phase 3 trial of low-dose tamoxifen in noninvasive breast cancer. SABCS 2022, VJOncology.
  2. Rajan KK. Оverall survival following breast conserving surgery and adjuvant radiotherapy compared with mastectomy for early stage breast cancer: a systematic review and meta-analysis. SABCS 2022.
  3. Krug D. Pathologic complete response and breastconserving surgery are associated with improved prognosis in patients with early stage triple-negative breast cancer treated with neoadjuvant chemotherapy. SABCS 2022, PD15-06 spotlight poster discussion 15.
  4. Thomssen C, Balic M, Harbeck N, Gnant M. St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer. Breast Care (Basel). 2021;16(2):135-43. doi: 10.1159/000516114
  5. Kuemmel S, Heil J, Rueland A, et al. A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients. Ann Surg. 2022;276(5):e553-62. doi: 10.1097/SLA.0000000000004572
  6. Montagna G, Mrdutt M, Sun SX, et al. The OPBC-04/EUBREAST-06/OMA Study Oncological Outcomes Following Sentinel Lymph Node Biopsy (SLNB) or Targeted Axillary Dissection (TAD) in Breast Cancer Patients Downstaging From Node Positive To Node Negative with Neoadjuvant Chemotherapy. SABCS 2022.
  7. Boughey JC. Alliance ACOSOG Z11102: impact of breast conservation therapy on local recurrence in pts with MIBC. SABCS 2022, VJOncology.
  8. Graeser M, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27(35):5887-92. doi: 10.1200/JCO.2008.19.9430
  9. Yadav S, Boddicker NJ, Na J, et al. GS4-04 Population-based Estimates of Contralateral Breast Cancer Risk among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2 and PALB2. SABCS 2022.
  10. Tolaney S, Barry W, Guo H, et al. Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). J Clin Oncol. 2017;35(15):511. doi: 10.1200/JCO.2017.35.15_suppl.511
  11. Tolaney S, Tarantino P, Graham N, et al. PD18-02 Adjuvant paclitaxel and trastuzumab trial (APT) for node-negative human epidermal growth factor receptor 2-positive (HER2+) breast cancer: final 10-year analyses. SABCS 2022.
  12. Shao Z, Pang D, Yang H, et al. Final analysis of the phase III PEONY trial: long-term efficacy and safety of neoadjuvant–adjuvant pertuzumab or placebo, plus trastuzumab and docetaxel, in patients with HER2-positive early or locally advanced breast cancer. SABCS 2022.
  13. Gupta S, Nair NS, Hawaldar R, et al. GS5-01 Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial. SABCS 2022.
  14. Johnston S, Toi M, O'Shaughnessy J, et al. GS1-09 Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes. SABCS 2022.
  15. Chavez-MacGregor M, Miao J, Pusztai L, et al. GS1-07 Results from a phase III randomized, placebocontrolled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207. SABCS 2022.
  16. Kang I, Forschmiedt JK, Loch MM, et al. Patient-reported Cognitive Impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status. SABCS 2022.
  17. Partridge AH, Niman SM, Ruggeri M, et al. Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsive breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14/BIG 8-13). SABCS 2022.
  18. Leone J, Hassett MJ, Freedman R, et al. PD6-08 Mortality risks over 20 years in men with stage I–III hormone receptor-positive breast cancer. Cancer Res. 2023;83(Suppl. 5):PD6-08.
  19. Fox S, Speirs V, Shaaban A. Male breast cancer: an update. Virchows Arch. 2022;480(1):85-93. doi: 10.1007/s00428-021-03190-7
  20. Colleoni M, Sun Z, Price KN, et al. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol. 2016;34(9):927-35. doi: 10.1200/JCO.2015.62.3504
  21. Leone JP, Leone J, Zwenger AO, et al. Prognostic Significance of Tumor Subtypes in Women With Breast Cancer According to Stage: A Population-based Study. Am J Clin Oncol. 2019;42(7):588-95. doi: 10.1097/COC.0000000000000563
  22. Wu Q, Hatse S, Kenis C, et al. PD6-03 Serum methylmalonic acid concentrations at breast cancer diagnosis strongly correlate with frailty: a retrospective cross-sectional study. SABCS 2022. Cancer Res. 2023;83(Suppl. 5):PD6-03.
  23. Boutin M, Presse N, Martineau T, et al. Mass spectrometry analysis of urinary methylmalonic acid to screen for metabolic vitamin B12 deficiency in older adults. Bioanalysis. 2020;12(10):693-705. doi: 10.4155/bio-2020-0106
  24. Gomes A, Ilter D, Low V, et al. Age-induced accumulation of methylmalonic acid promotes tumour progression. Nature. 2020;585(7824):283-7. doi: 10.1038/s41586-020-2630-0

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. The incidence of breast cancer – BC (invasive and DCIS) in the overall group (a) and patients with DCIS (b) in the TAM 01 study [1].

Download (137KB)
Indexing metadata
3. Fig. 2. A meta-analysis of 37 studies evaluating the effect of surgery extent on overall survival (OS) in patients with stage I–III BC [2].

Download (298KB)
Indexing metadata
4. Fig. 3. The effect of the surgery extent on the relapse-free survival – RFS (a) and OS (b) in patients with triple-negative BC after neoadjuvant chemotherapy (NACT) in a GBG combined analysis [3].

Download (176KB)
Indexing metadata
5. Fig. 4. Comparison of locoregional recurrence (a) and all invasive recurrence (b) rates between groups that received TAD and sentinel lymph node biopsy in OPBC-04/EUBREAST-06/OMA study [6].

Download (152KB)
Indexing metadata
6. Fig. 5. Risk and incidence of contralateral breast cancer in premenopausal and menopausal patients in the CARRIERS study [9].

Download (166KB)
Indexing metadata
7. Fig. 6. Event-free survival (a), disease-free survival (b) and overall survival (c) in PEONY trial [12].

Download (202KB)
Indexing metadata
8. Fig. 7. Frequency of pathological complete response (pCRs) in the TMC study in patients younger than 50 (a) and older than 50 (b) in the TMC randomized phase III clinical study [13].

Download (127KB)
Indexing metadata
9. Fig. 8. Survival without invasive recurrence (a) and without distant metastases (b) in the MonarchE study [13].

Download (227KB)
Indexing metadata
10. Fig. 9. Survival without invasive recurrence (a) and OS (b) in SWOG study S1207 in premenopausal women [15].

Download (199KB)
Indexing metadata
11. Fig. 10. The risk of pronounced cognitive decline in premenopausal and menopausal patients at different times after initial treatment [16].

Download (103KB)
Indexing metadata
12. Fig. 11. POSITIVE study design [17].

Download (81KB)
Indexing metadata
13. Fig. 12. The proportion of relapses (a) and distant metastases (b) of BC in patients in the POSITIVE study and the control group – SOFT/TEXT studies [17].

Download (185KB)
Indexing metadata
14. Fig. 13. Three-year overall relapse rate (BCFI) in different subgroups of patients [17].

Download (284KB)
Indexing metadata
15. Fig. 14. The proportion of deaths from BC in males with BC, according to the SEER database analysis, depending on the stage (a) and the status of the lymph nodes (b) [18].

Download (217KB)
Indexing metadata
16. Fig. 15. The proportion of relapses in women with HR+ HER2-negative BC depending on the number of affected lymph nodes (a) and deaths from BC in stage III disease (b) [20, 21].

Download (127KB)
Indexing metadata

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies